Figure 7.
Schematic of canonical Hh pathway. (A) SMO antagonist–responsive cell (eg, BCC). (B-D) Revised schematic of Hh signaling in SMO-sensitive, SMO-resistant, and decitabine-treated AML cells.
Schematic of canonical Hh pathway. (A) SMO antagonist–responsive cell (eg, BCC). (B-D) Revised schematic of Hh signaling in SMO-sensitive, SMO-resistant, and decitabine-treated AML cells.
